TEC Kinase Inhibitors
1 drugsAbout TEC Kinase
TEC Kinase is a non-receptor tyrosine kinase involved in signaling pathways that influence cell growth, differentiation, and immune responses. It functions downstream of cell surface receptors, playing a role in various cellular processes.
Currently, there is no genetic evidence available linking TEC Kinase to specific diseases, highlighting the need for further research into its role in disease pathogenesis. Despite the lack of genetic validation, the existence of an approved drug suggests therapeutic potential.
LITFULO (Pfizer) is the only FDA-approved drug targeting TEC Kinase, a small molecule approved in 2023. It is classified within the 'Other' therapeutic area, suggesting applications beyond common areas.
Top TEC Kinase Drugs
Pfizer is the only company with an approved drug targeting TEC Kinase.
Low competition represents an opportunity, but also a risk due to limited validation.
TEC Kinase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TEC Kinase, using small molecule modality.
Explore alternative modalities like antibodies to differentiate from existing therapies.
TEC Kinase Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TEC Kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 7 | 1 | 2 | 4 | 33% |
| Phase 3 | 3 | 1 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TEC Kinase Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for TEC Kinase was LITFULO in 2023.
Recent approval indicates renewed interest, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TEC Kinase. A trial counts if an approved drug acting on TEC Kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.